Endocyte, Inc. (NASDAQ:ECYT) Files An 8-K Results of Operations and Financial Condition

Endocyte, Inc. (NASDAQ:ECYT) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 Results of Operations and Financial Condition.

Story continues below

On November 7, 2018, Endocyte, Inc. (the “Company”) announced its results of operations for the three months ended September 30, 2018. A copy of the Company’s earnings release is furnished herewith as Exhibit 99.1.

The information in this Item 2.02 and in Item 9.01 of this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and in Item 9.01 of this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 Financial Statements and Exhibits.

A copy of the Company’s earningsrelease is furnished, but not filed, as Exhibit 99.1 hereto.

(d)Exhibits

Exhibit Index

Exhibit No.

Description

99.1

Press release issued on November 7, 2018


ENDOCYTE INC Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 ecyt_Ex99_1 Exhibit 99.1 Investor Contact: Michael Schaffzin,…
To view the full exhibit click here

About Endocyte, Inc. (NASDAQ:ECYT)

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

An ad to help with our costs